CA2723429C - Thienopyridone derivatives as amp-activated protein kinase (ampk) activators - Google Patents

Thienopyridone derivatives as amp-activated protein kinase (ampk) activators Download PDF

Info

Publication number
CA2723429C
CA2723429C CA2723429A CA2723429A CA2723429C CA 2723429 C CA2723429 C CA 2723429C CA 2723429 A CA2723429 A CA 2723429A CA 2723429 A CA2723429 A CA 2723429A CA 2723429 C CA2723429 C CA 2723429C
Authority
CA
Canada
Prior art keywords
pyridin
hydroxy
dihydro
thieno
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2723429A
Other languages
English (en)
French (fr)
Other versions
CA2723429A1 (en
Inventor
Daniel Cravo
Franck Lepifre
Sophie Hallakou-Bozec
Christine Charon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40756916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2723429(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CA2723429A1 publication Critical patent/CA2723429A1/en
Application granted granted Critical
Publication of CA2723429C publication Critical patent/CA2723429C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2723429A 2008-05-05 2009-04-08 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators Active CA2723429C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08290423 2008-05-05
EP08290423.6 2008-05-05
PCT/EP2009/002606 WO2009135580A1 (en) 2008-05-05 2009-04-08 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Publications (2)

Publication Number Publication Date
CA2723429A1 CA2723429A1 (en) 2009-11-12
CA2723429C true CA2723429C (en) 2016-10-11

Family

ID=40756916

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2723429A Active CA2723429C (en) 2008-05-05 2009-04-08 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Country Status (26)

Country Link
US (1) US8604202B2 (enExample)
EP (1) EP2280952B1 (enExample)
JP (1) JP5536757B2 (enExample)
KR (2) KR101648593B1 (enExample)
CN (1) CN102015676B (enExample)
AR (1) AR071530A1 (enExample)
AU (1) AU2009243811B2 (enExample)
BR (1) BRPI0910832B8 (enExample)
CA (1) CA2723429C (enExample)
CO (1) CO6331304A2 (enExample)
CY (1) CY1113112T1 (enExample)
DK (1) DK2280952T3 (enExample)
EA (1) EA020773B1 (enExample)
EC (1) ECSP10010654A (enExample)
ES (1) ES2388485T3 (enExample)
HR (1) HRP20120549T1 (enExample)
IL (1) IL208988A (enExample)
MX (1) MX2010011916A (enExample)
MY (1) MY160357A (enExample)
NZ (1) NZ589690A (enExample)
PL (1) PL2280952T3 (enExample)
PT (1) PT2280952E (enExample)
SI (1) SI2280952T1 (enExample)
UA (1) UA103617C2 (enExample)
WO (1) WO2009135580A1 (enExample)
ZA (1) ZA201008722B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011121109A1 (en) 2010-04-02 2011-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012028582A1 (de) 2010-09-01 2012-03-08 Bayer Cropscience Ag Herbizid wirksame ketosultame und diketopyridine
EP2683690A1 (en) * 2011-03-07 2014-01-15 GlaxoSmithKline LLC Quinolinone derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (en) * 2012-06-29 2014-01-01 Poxel Thienopyridone derivatives useful as activators of AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
EP3089748A4 (en) 2014-01-02 2017-09-27 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
WO2015114663A1 (en) 2014-01-30 2015-08-06 Council Of Scientific & Industrial Research Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties
WO2016205534A1 (en) * 2015-06-16 2016-12-22 Lazo John S Inhibitors of ptp4a3 for the treatment of cancer
RS61919B1 (sr) 2015-06-25 2021-06-30 Univ Health Network Inhibitori hpk1 i postupci za njihovo korišćenje
CN108463218A (zh) 2015-09-30 2018-08-28 药物分子研究所 减弱寄生虫毒性的方法
US11584755B2 (en) 2017-09-26 2023-02-21 Ideaya Biosciences, Inc. Dihydrothieno[3,2-b]pyridine compounds
WO2019106087A1 (en) * 2017-11-29 2019-06-06 Syddansk Universitet Ampk inhibitors
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN116322663A (zh) 2020-09-30 2023-06-23 比奥维拉迪维治疗股份有限公司 Ampk激活剂及其使用方法
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds
AU2022391025A1 (en) 2021-11-19 2024-06-06 The Brigham And Women's Hospital, Inc. Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
DE4444815A1 (de) * 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
AR040123A1 (es) * 2002-05-31 2005-03-16 Upjohn Co Compuestos tiofeno, antihelminticos e insecticidas
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
WO2006093518A2 (en) * 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
US7563813B2 (en) * 2005-05-13 2009-07-21 Wyeth Iminothiazolidinone derivatives as SFRP-1 antagonists
EP1754483A1 (en) * 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
JP2009520015A (ja) 2005-12-20 2009-05-21 リヒター ゲデオン ニュルト 新規な化合物
KR101630466B1 (ko) * 2008-04-11 2016-06-14 메르크 파텐트 게엠베하 Ａｍｐ-활성화 단백질 키나아제(ａｍｐｋ) 활성화제로서의 티에노피리돈 유도체

Also Published As

Publication number Publication date
EP2280952B1 (en) 2012-06-27
US8604202B2 (en) 2013-12-10
CY1113112T1 (el) 2016-04-13
EA201001733A1 (ru) 2011-06-30
CO6331304A2 (es) 2011-10-20
AU2009243811B2 (en) 2014-04-10
AR071530A1 (es) 2010-06-23
CN102015676B (zh) 2014-05-28
PL2280952T3 (pl) 2012-10-31
HRP20120549T1 (hr) 2012-07-31
ZA201008722B (en) 2012-01-25
SI2280952T1 (sl) 2012-09-28
HK1156313A1 (en) 2012-06-08
MY160357A (en) 2017-02-28
EP2280952A1 (en) 2011-02-09
ECSP10010654A (es) 2011-01-31
CN102015676A (zh) 2011-04-13
US20110060001A1 (en) 2011-03-10
PT2280952E (pt) 2012-09-28
IL208988A (en) 2016-02-29
KR101648593B1 (ko) 2016-08-16
KR20110010757A (ko) 2011-02-07
CA2723429A1 (en) 2009-11-12
BRPI0910832B1 (pt) 2020-09-15
DK2280952T3 (da) 2012-07-23
KR20160038065A (ko) 2016-04-06
ES2388485T3 (es) 2012-10-15
BRPI0910832A8 (pt) 2016-07-12
JP2011519876A (ja) 2011-07-14
JP5536757B2 (ja) 2014-07-02
BRPI0910832A2 (pt) 2015-08-11
MX2010011916A (es) 2010-11-26
WO2009135580A1 (en) 2009-11-12
AU2009243811A1 (en) 2009-11-12
NZ589690A (en) 2012-07-27
IL208988A0 (en) 2011-01-31
EA020773B1 (ru) 2015-01-30
UA103617C2 (ru) 2013-11-11
BRPI0910832B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
US8604202B2 (en) Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators
US8563729B2 (en) Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators
EP2285786B1 (en) Quinoxalinedione derivatives
AU2013283239A1 (en) Thienopyridone derivatives useful as activators of AMPK
HK1156313B (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140407

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20251008

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251107